| 1.03 -0.03 (-2.83%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.29 | 1-year : | 1.46 |
| Resists | First : | 1.11 | Second : | 1.25 |
| Pivot price | 1.02 |
|||
| Supports | First : | 0.88 | Second : | 0.74 |
| MAs | MA(5) : | 1.06 |
MA(20) : | 1.03 |
| MA(100) : | 1.16  |
MA(250) : | 1.23 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 80.3 |
D(3) : | 81.8 |
| RSI | RSI(14): 44.5 |
|||
| 52-week | High : | 1.74 | Low : | 0.83 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ QNCX ] has closed below upper band by 49.6%. Bollinger Bands are 27.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.08 - 1.09 | 1.09 - 1.1 |
| Low: | 1.02 - 1.02 | 1.02 - 1.03 |
| Close: | 1.02 - 1.03 | 1.03 - 1.04 |
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Tue, 02 Apr 2024
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023 - InvestorPlace
Mon, 01 Apr 2024
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results - Business Wire
Fri, 08 Mar 2024
The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech - Yahoo Finance
Thu, 22 Feb 2024
Quince Therapeutics Launches Scientific Advisory Board - Business Wire
Thu, 15 Feb 2024
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors - Yahoo Finance
Thu, 15 Feb 2024
Quince Therapeutics Appoints Rajiv Patni to Board of Directors - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 17 (%) |
| Held by Institutions | 28.1 (%) |
| Shares Short | 1,860 (K) |
| Shares Short P.Month | 1,900 (K) |
| EPS | -0.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.98 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -11.4 % |
| Return on Equity (ttm) | -33.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -1.23 |
| PEG Ratio | 0 |
| Price to Book value | 0.52 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|